Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABOVE: Meropenem Adjuvant Therapy for Carbapenem-Resistant Enterobacterales Bloodstream Infections
NCT04876430Phase 3Terminated
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem in bloodstream infection (BSI), Enterobacterales infection, sponsored by Hospital de Clínicas de Porto Alegre. Started May 2021; status: terminated.
02
Drugs
meropenem
03
Conditions
bloodstream infection (BSI)Enterobacterales infection
Beyond the preview
Go deeper on NCT04876430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876430.